28 September 2010
Preemptive administration of recombinant factor VII (rVIIa) in patients transplanted due to fulminant Wilson’s disease
Maria M. Czuprynska, Marta Wawrzynowicz-Syczewska, Lidia Jureczko, Janina Andrzejewska, Konrad Jarosz, Janusz Trzebicki, Marek Pacholczyk, Andrzej Chmura, Maciej WojcickiAnn Transplant 2010; 15(3): 7-10 :: ID: 881163
Abstract
Background: Fulminant liver failure (FLF) is a severe clinical condition usually accompanied by a coagulopathy, which is one of the key selection criteria for liver transplantation. Prolongation of prothrombin time can vary between etiologies of FHF, being one of the worst in fulminant presentation of Wilson’s disease. Although INR value is not predictive for hemorrhage, it is commonly accepted that INR >1.9 carries a substantial risk of intraoperative bleeding. We tested the hypothesis that preemptive administration of recombinant factor VII (rFVIIa) is a safe and efficacious approach allowing performance of urgent liver transplantation without significant bleeding and thrombotic complications.
Material/Methods: In 14 analyzed cases of fulminant Wilson’s disease subjected for orthotopic liver transplantation (OLT), a single bolus of rFVIIa 10 minutes before skin incision was given routinely in a median dose of 55.9 microg/kg.
Results: Median value of INR dropped from 3.1 to 1.2 30 minutes after rFVIIa administration. Transfusion requirements in those cases did not differ from standard transfusion requirements of PRBCs observed in elective OLTx in our center (6 units v. 5, respectively). Recurrent bleeding was noted in 1 patient with the rupture of aorta. One-year survival rate in the studied group was 85.7%. Thrombotic complications were noted in none of the patients.
Conclusions: We conclude that preemptive use of rFVIIa allows performance of a broad surgical procedure without hemorrhagic complications and without increased risk of thromboembolic events in patients with severe coagulopathy.
Keywords: Liver Transplantation, fulminant hepatic failure, Wilson’s disease, coagulation disorders, recombinant factor VII
In Press
20 Mar 2024 : Original article
Transplant Nephrectomy: A Comparative Study of Timing and Techniques in a Single InstitutionAnn Transplant In Press; DOI: 10.12659/AOT.942252
28 Mar 2024 : Original article
Association Between FEV₁ Decline Rate and Mortality in Long-Term Follow-Up of a 21-Patient Pilot Clinical T...Ann Transplant In Press; DOI: 10.12659/AOT.942823
02 Apr 2024 : Original article
Liver Transplantation from Brain-Dead Donors with Hepatitis B or C in South Korea: A 2014-2020 Korean Organ...Ann Transplant In Press; DOI: 10.12659/AOT.943588
02 Apr 2024 : Original article
Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...Ann Transplant In Press; DOI: 10.12659/AOT.943281
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860